Expert Interview
A Third Look: Discussing the standard of care and the potential of NAYZILAM (midazolam), a nasal spray able to return patients experiencing seizure clusters back to baseline function within 90 minutes
Ticker(s): UCB- Adult Epileptologist and Clinical Assistant Professor of Neurology at NYU Grossman School of Medicine (Jun 2018-Present). Dr. Billakota is
- board certified in Epilepsy, Clinical Neurophysiology, and Neurology. She
- specializes in the treatment of epilepsy with a special interest in women with epilepsy. Dr. Billakota has
- published varies studies such as cannabinoid therapy in epilepsy and sleep disordered breathing, neuroendocrine function and clinical SUDEP risk in
- patients with epilepsy.
- treats about 5-10 patients over the age of 12 every month with status epilepticus.
- very familiar with the results from P2 and ongoing P3 RAISE trial of ganaxolone in status epilepticus.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
